Health Care & Life Sciences » Biotechnology | Applied Genetic Technologies Corp.

Applied Genetic Technologies Corp. | Income Statement

Fiscal year is July-June. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
-
-
2,354.00
47,361.00
39,473.00
24,186
Cost of Goods Sold (COGS) incl. D&A
285.00
334.00
-
-
-
-
Gross Income
285.00
334.00
-
-
-
-
SG&A Expense
4,251.00
13,351.00
26,510.00
48,883.00
36,659.00
45,395
EBIT
4,536.00
13,685.00
24,532.00
2,089.00
1,902.00
22,384
Unusual Expense
1,215.00
3,345.00
-
-
-
-
Non Operating Income/Expense
942.00
1,080.00
2.00
3.00
47.00
125
Interest Expense
191.00
-
-
-
-
-
Pretax Income
4,990.00
15,908.00
24,318.00
1,381.00
2,807.00
21,208
Income Tax
-
-
-
-
2,400.00
72
Consolidated Net Income
4,990.00
15,908.00
24,318.00
1,381.00
407.00
21,300
Net Income
4,990.00
15,908.00
24,318.00
1,381.00
407.00
21,300
Net Income After Extraordinaries
4,990.00
15,908.00
24,318.00
1,381.00
407.00
21,300
Net Income Available to Common
4,990.00
15,908.00
24,318.00
1,381.00
407.00
21,300
EPS (Basic)
1.20
4.46
1.50
0.08
0.02
1.18
Basic Shares Outstanding
4,146.00
3,568.00
16,253.00
17,810.00
18,072.00
18,105
EPS (Diluted)
1.20
4.46
1.50
0.08
0.02
1.18
Diluted Shares Outstanding
4,146.00
3,568.00
16,253.00
17,810.00
18,385.00
18,105
EBITDA
4,251.00
13,351.00
24,156.00
1,522.00
2,814.00
21,209
Non-Operating Interest Income
10.00
42.00
216.00
711.00
952.00
1,301

About Applied Genetic Technologies

View Profile
Address
14193 NW
Alachua Florida 32615
United States
Employees -
Website http://www.agtc.com
Updated 07/08/2019
Applied Genetic Technologies Corp. is a clinical-stage biotechnology company, which engages in the development of gene therapy products designed to transform the lives of patients with severe diseases in ophthalmology. Its product candidates are designed to treat X-linked retinoschisis, Achromatopsia, and X-linked retinitis pigmentosa. The company was founded by Richard Jude Samulski, Nicholas Muzyczka, William W.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.